Search

Your search keyword '"Plavix (Medication)"' showing total 159 results
Start Over Descriptor "Plavix (Medication)" Journal fair disclosure wire
159 results on '"Plavix (Medication)"'

1. BristolMyers Squibb Co Investor Event - Final

Subjects
Bristol-Myers Squibb Co., Pharmaceutical industry, Business, Plavix (Medication)
Abstract

Presentation TIMOTHY POWER, VP & HEAD OF IR, BRISTOL-MYERS SQUIBB COMPANY: This is Tim Power from Bristol-Myers Squibb. You're very welcome to our presentation at ESC 2022. As you know, [...]

Published
2022

2. Q3 2020 Sanofi SA Earnings Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Dupixent (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Investor Call on the Q3 2020 earnings. I would now like to turn the call over [...]

Published
2020

3. Q4 2019 Cytosorbents Corp Earnings Call - Final

Subjects
Chief operating officers, Finance, Company earnings/profit, Business, Plavix (Medication)
Abstract

Presentation OPERATOR: Good afternoon, and welcome to the CytoSorbents 2019 Financial and Operating Results Conference call. (Operator Instructions) Please be advised that the call will be recorded at the company's [...]

Published
2020

4. Event Brief of Q3 2019 Sanofi SA Earnings Call - Final

Subjects
Citigroup Inc., Sanofi S.A., Societe Generale S.A., Banking industry, Financial services, Pharmaceutical industry, Financial services industry, Banking industry, Business, Dupixent (Medication), Praluent (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . David Loew - Sanofi,EVP of Pasteur . Dieter Weinand - Sanofi,EVP of Primary Care . George Grofik - Sanofi,Head of IR . Jean-Baptiste Chasseloup de Chatillon - [...]

Published
2019

5. Q3 2019 Sanofi SA Earnings Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry -- International economic relations, Business, Dupixent (Medication), Praluent (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Sanofi Third Quarter 2019 Earnings Conference Call. I would like to turn the call over to [...]

Published
2019

6. Event Brief of Q4 2018 Sanofi SA Earnings Call - Final

Subjects
United States. Food and Drug Administration, Societe Generale S.A., Citigroup Inc., Sanofi S.A., Banking industry, Financial services, Pharmaceutical industry, Banking industry, Financial services industry, Business, Cablivi (Medication), Dupixent (Medication), Eloctate (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Dieter Weinand - Sanofi,EVP . George Grofik - Sanofi,Head of IR . Jean-Baptiste Chasseloup de Chatillon - Sanofi,Executive VP & CFO . John C. Reed - Sanofi,Executive [...]

Published
2019

7. Q4 2018 Sanofi SA Earnings Call - Final

Subjects
United States. Food and Drug Administration, Sanofi S.A., Pharmaceutical industry, Business, Cablivi (Medication), Dupixent (Medication), Eloctate (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, welcome to the Sanofi Q4 and Full Year 2018 Earnings Results Conference Call and Live Webcast. I am Emma, the Chorus Call operator. (Operator Instructions) [...]

Published
2019

8. Event Brief of Q2 2016 Sanofi SA Earnings Call - Final

Subjects
Deutsche Bank AG (Frankfurt, Germany), Sanofi S.A., Banking industry, Pharmaceutical industry, Banking industry, Business, Lantus (Medication), Praluent (Medication), Plavix (Medication), Zetia (Medication)
Abstract

CORPORATE PARTICIPANTS . George Grofik - Sanofi SA,VP, IR . Olivier Brandicourt - Sanofi SA,CEO . Elias Zerhouni - Sanofi SA,President Global R&D . Jerome Contamine - Sanofi SA,EVP, CFO [...]

Published
2016

9. Q2 2016 Sanofi SA Earnings Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Lantus (Medication), Praluent (Medication), Plavix (Medication), Zetia (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, good afternoon. Welcome to the Sanofi Q2 2016 results conference call and live webcast. I am Celina, the Chorus Call operator. I would like to [...]

Published
2016

10. Event Brief of Q2 2015 Sanofi SA Earnings Call - Final

Subjects
Deutsche Bank AG (Frankfurt, Germany), Societe Generale S.A., Sanofi S.A., Banking industry, Pharmaceutical industry, Business, Aubagio (Medication), Lantus (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

CORPORATE PARTICIPANTS . Sebastien Martel - Sanofi SA,VP IR . Olivier Brandicourt - Sanofi SA,CEO . Jerome Contamine - Sanofi SA,EVP, CFO . Olivier Charmeil - Sanofi SA,EVP Vaccines . [...]

Published
2015

11. Q2 2015 Sanofi SA Earnings Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Aubagio (Medication), Lantus (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, welcome to the Sanofi 2015 Q2 earnings call. I will now hand over to Mr. Sebastien Martel, head of Investor Relations. Sir, please go ahead. [...]

Published
2015

12. Sanofi SA at Barclays Healthcare Conference - Final

Subjects
Barclays Capital Inc. -- Conferences, meetings and seminars, Sanofi S.A. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Antilipemic agents -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Health care industry, Business, Plavix (Medication)
Abstract

Presentation MICHAEL LEUCHTEN, ANALYST, BARCLAYS CAPITAL: So thank you for joining us. It's my pleasure to introduce Dr. Paul Chew, the Chief Medical Officer at Sanofi. Dr. Chew will give [...]

Published
2014

13. Event Brief of Q2 2013 Sanofi SA Earnings Conference Call - Final

Subjects
JPMorgan Chase & Co., Sanofi S.A., Banking industry, Pharmaceutical industry, Banking industry, Business, Aubagio (Medication), Lantus (Medication), Lemtrada (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Sebastien Martel - Sanofi SA,VP, IR . Christopher Viehbacher - Sanofi SA,CEO . Peter Guenter - Sanofi SA,EVP, Global Commercial Operations . Pascale Witz - Sanofi SA,EVP, [...]

Published
2013

14. Q2 2013 Sanofi SA Earnings Conference Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Aubagio (Medication), Lantus (Medication), Lemtrada (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, welcome to Sanofi second-quarter results 2013. I now hand over to Sebastien Martel, Head Investor Relations. Sir, please go ahead. SEBASTIEN MARTEL, VP, IR, SANOFI [...]

Published
2013

15. Sanofi SA at Bank of America Merrill Lynch Health Care Conference - Final

Subjects
Sanofi S.A. -- Conferences, meetings and seminars, Cholesterol -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Health care industry, Business, Aubagio (Medication), Lantus (Medication), Plavix (Medication)
Abstract

Presentation UNIDENTIFIED PARTICIPANT: (audio in progress) introduce the first of the European companies at this conference this year, which is Sanofi and from the Company have Paul Chew, Chief Scientific [...]

Published
2013

16. BristolMyers Squibb 2013 Annual Meeting of Stockholders - Final

Subjects
Johnson & Johnson -- Conferences, meetings and seminars -- Officials and employees, Bristol-Myers Squibb Co. -- Conferences, meetings and seminars -- Officials and employees, Stockholders -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Officials and employees, Business, Plavix (Medication)
Abstract

Presentation JIM CORNELIUS, CHAIRMAN, BRISTOL-MYERS SQUIBB: Ladies and gentleman, my clock shows 10 o'clock. We'll convene this annual meeting of Bristol-Myers Squibb to order. Good morning. Welcome. I'm Jim Cornelius, [...]

Published
2013

17. Event Brief of Q1 2013 Sanofi SA Earnings Conference Call - Final

Subjects
Morgan Stanley, Sanofi S.A., Securities industry, Pharmaceutical industry, Securities industry, Business, American Diabetes Association, Aubagio (Medication), Lantus (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Sebastien Martel - Sanofi SA,VP, IR . Christopher Viehbacher - Sanofi SA,CEO . Hanspeter Spek - Sanofi SA,President, Global Operations . Jerome Contamine - Sanofi SA,EVP, CFO [...]

Published
2013

18. Q1 2013 Sanofi SA Earnings Conference Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Aubagio (Medication), Lantus (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, welcome to the Sanofi 2013 first-quarter results conference call. I will now hand over to Mr. Sebastien Martel. Sir, please go ahead. SEBASTIEN MARTEL, VP, [...]

Published
2013

19. Event Brief of Full Year 2012 Sanofi SA Earnings Conference Call - Final

Subjects
Credit Suisse Group AG, BNP Paribas S.A., Sanofi S.A., Banking industry, Financial services industry, Pharmaceutical industry, Financial services industry, Banking industry, Business, Aubagio (Medication), Fluzone (Vaccine), Lantus (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Sebastien Martel - Sanofi SA,VP, IR . Christopher Viehbacher - Sanofi SA,CEO . Jerome Contamine - Sanofi SA,EVP, CFO . Hanspeter Spek - Sanofi SA,President, Global Operations [...]

Published
2013

20. Full Year 2012 Sanofi SA Earnings Conference Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Aubagio (Medication), Fluzone (Vaccine), Lantus (Medication), Plavix (Medication)
Abstract

Presentation SEBASTIEN MARTEL, VP, IR, SANOFI SA: Okay, well, I guess we're ready to go. Good afternoon to those here in La Boetie, our headquarters. Just a little anecdote, I'm [...]

Published
2013

21. Event Brief of Q4 2012 Bristol-Myers Squibb Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co., AstraZeneca PLC, Pharmaceutical industry, Business, Onglyza (Medication), Yervoy (Medication), Sprycel (Medication), Plavix (Medication), Bydureon (Medication)
Abstract

CORPORATE PARTICIPANTS . John Elicker - Bristol-Myers Squibb Co,SVP IR & Public Affairs . Lamberto Andreotti - Bristol-Myers Squibb Co,CEO . Charlie Bancroft - Bristol-Myers Squibb Co,CFO . Giovanni Caforio [...]

Published
2013

22. Q4 2012 BristolMyers Squibb Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co., AstraZeneca PLC, Pharmaceutical industry, Business, Abilify (Medication), Onglyza (Medication), Yervoy (Medication), Sprycel (Medication), Plavix (Medication), Bydureon (Medication)
Abstract

Presentation OPERATOR: Good day. Welcome to the fourth quarter 2012 Earnings Release Conference Call. This call is being recorded. At this time I would like to turn the call over [...]

Published
2013

23. Event Brief of Q3 2012 Sanofi SA Earnings Conference Call - Final

Subjects
Morgan Stanley, JPMorgan Chase & Co., Sanofi S.A., Banking industry, Securities industry, Pharmaceutical industry, Securities industry, Banking industry, Business, Aubagio (Medication), Cerezyme (Medication), Eloxatin (Medication), Lantus (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Sebastien Martel - Sanofi SA,VP, IR . Christopher Viehbacher - Sanofi SA,CEO . Hanspeter Spek - Sanofi SA,President, Global Operations . Olivier Charmeil - Sanofi SA,SVP, Vaccines [...]

Published
2012

24. The Medicines Company at Morgan Stanley Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Drugs -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Securities industry, Business, Cleviprex (Medication), Angiomax (Medication), Plavix (Medication)
Abstract

Presentation DAVE FRIEDMAN, ANALYST, MORGAN STANLEY: All right, thanks, everyone, for joining us here. I'm Dave Friedman, biotech analyst. And in terms of the disclosure statement, personal and Morgan Stanley [...]

Published
2012

25. Event Brief of Half Year 2012 Sanofi SA Earnings Conference Call - Final

Subjects
Morgan Stanley, Securities industry, Securities industry, Business, Avapro (Medication), Lantus (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Sebastien Martel - Sanofi SA,VP, IR . Christopher Viehbacher - Sanofi SA,CEO . Hanspeter Spek - Sanofi SA,President, Global Operations . Olivier Charmeil - Sanofi SA,SVP, Vaccines [...]

Published
2012

26. Event Brief of Q2 2012 Bristol-Myers Squibb Earnings Conference Call - Final

Subjects
Pharmaceutical industry, Business, Yervoy (Medication), Avapro (Medication), Byetta (Medication), Plavix (Medication), Bydureon (Medication)
Abstract

CORPORATE PARTICIPANTS . John Elicker - Bristol-Myers Squibb Co,SVP, Public Affairs and IR . Lamberto Andreotti - Bristol-Myers Squibb Co,CEO . Charlie Bancroft - Bristol-Myers Squibb Co,CFO . Elliott Sigal [...]

Published
2012

27. Q2 2012 BristolMyers Squibb Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co. -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Yervoy (Medication), Avapro (Medication), Byetta (Medication), Plavix (Medication), Bydureon (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to today's Bristol-Myers Squibb second-quarter 2012 earnings release conference call. Just a reminder, today's call is being recorded. Now, for opening [...]

Published
2012

28. BristolMyers Squibb at Sanford C. Bernstein & Co. Strategic Decisions Conference - Final

Subjects
Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Generic drugs -- Conferences, meetings and seminars, Corporations -- Conferences, meetings and seminars, Anticoagulants (Medicine) -- Conferences, meetings and seminars, Biological response modifiers -- Conferences, meetings and seminars, Warfarin -- Conferences, meetings and seminars, Liver diseases -- Care and treatment -- Conferences, meetings and seminars, Hepatitis C -- Care and treatment -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Plavix (Medication)
Abstract

Presentation TIM ANDERSON, ANALYST, SANFORD C. BERNSTEIN: Okay. So we're going to begin. I'm Tim Anderson, the Global Pharmaceutical Analyst for Sanford Bernstein. We have joining us right now Bristol-Myers [...]

Published
2012

29. Sanofi SA at Deutsche Bank AG Health Care Conference - Final

Subjects
Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Medical care, Cost of -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Medicare -- Conferences, meetings and seminars, Emerging markets -- Conferences, meetings and seminars, Metastasis -- Care and treatment -- Conferences, meetings and seminars, Health care industry -- Mergers, acquisitions and divestments -- Conferences, meetings and seminars, Vaccines -- Conferences, meetings and seminars, Hypercholesterolemia -- Care and treatment -- Conferences, meetings and seminars, Monoclonal antibodies -- Conferences, meetings and seminars, Health care industry, Company acquisition/merger, Business, Fabrazyme (Medication), Plavix (Medication)
Abstract

Presentation UNIDENTIFIED PARTICIPANT: Okay. Thanks for everybody for being in the room. Our next session is with Sanofi, and I'm pleased to introduce their Chief Financial Officer, Jerome Contamine. JEROME [...]

Published
2012

30. Q1 2012 Sanofi SA Earnings Conference Call - Final

Subjects
Business, Cerezyme (Medication), Rebif (Medication), Lantus (Medication), Lovenox (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Welcome to the Sanofi conference call. I now hand over to Mr. Sebastien Martel. Sir, please, go ahead. SEBASTIEN MARTEL, VP IR, SANOFI: Thank you. Hello, everyone, and [...]

Published
2012

31. Event Brief of Q1 2012 Sanofi SA Earnings Conference Call - Final

Subjects
Business, Cerezyme (Medication), Lantus (Medication), Lovenox (Medication), Plavix (Medication)
Abstract

PARTICIPANTS . Sebastien Martel, Sanofi, VP IR . Chris Viehbacher, Sanofi, CEO . Hanspeter Spek, Sanofi, President, Global Operations . Jerome Contamine, Sanofi, EVP, CFO . Tim Anderson, Sanford Bernstein, [...]

Published
2012

32. NANOSPHERE INC at Roth Capital Partners OC Growth Stock Conference - Final

Subjects
Nanosphere Inc. -- Conferences, meetings and seminars -- Growth, Coronary heart disease -- Development and progression -- Conferences, meetings and seminars, Anticoagulants (Medicine) -- Conferences, meetings and seminars, Cross infection -- Development and progression -- Conferences, meetings and seminars, Medical errors -- Conferences, meetings and seminars, Infection -- Development and progression -- Conferences, meetings and seminars, Warfarin -- Conferences, meetings and seminars, Cardiac patients -- Conferences, meetings and seminars, Property and casualty insurance industry -- Conferences, meetings and seminars -- Growth, Medical care, Cost of -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars -- Growth, Personal care appliances industry -- Conferences, meetings and seminars -- Growth, Nosocomial infections -- Development and progression -- Conferences, meetings and seminars, Microbiology -- Conferences, meetings and seminars -- Growth, Company growth, Business, Plavix (Medication)
Abstract

Presentation UNIDENTIFIED PARTICIPANT: I think we will get started here. Our next presentation, we have Nanosphere, a covered company. With us presenting today we have the President and CEO, Bill [...]

Published
2012

33. Event Brief of Q4 and Full Year 2011 The Medicines Company Earnings Conference Call - Final

Subjects
JPMorgan Chase & Co. -- Intellectual property -- Planning, Banking industry -- Intellectual property -- Planning, Company business planning, Banking industry, Business, Angiomax (Medication), Plavix (Medication)
Abstract

PARTICIPANTS . Michael Mitchell, The Medicines Company, IR . Clive Meanwell, The Medicines Company, Chairman & CEO . Glenn Sblendorio, The Medicines Company, EVP & CFO . Dimitri Goundis, The [...]

Published
2012

34. Full Year 2011 Sanofi SA Earnings Conference Call - Final

Subjects
Biological products industry, Executions and executioners, Corporations, Hypercholesterolemia, Pharmaceutical industry, Business, Cerezyme (Medication), Fabrazyme (Medication), Lantus (Medication), Plavix (Medication)
Abstract

Presentation SEBASTIEN MARTEL, VP - IR, SANOFI: Okay, I think we're ready to roll so good afternoon and welcome to Sanofi 2011 Annual Results. Thanks a lot for those of [...]

Published
2012

35. Event Brief of Q4 2011 Bristol-Myers Squibb Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co., Medicare, Liver cancer, Pharmaceutical industry, Business, Yervoy (Medication), Plavix (Medication)
Abstract

PARTICIPANTS . John Elicker, Bristol Myers Squibb Co, SVP IR . Lamberto Andreotti, Bristol Myers Squibb Co, CEO . Charlie Bancroft, Bristol Myers Squibb Co, EVP and CFO . Tony [...]

Published
2012

36. Q4 2011 BristolMyers Squibb Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co., Medicare, Liver cancer, Pharmaceutical industry, Business, Yervoy (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Good day and welcome to today's Bristol-Myers Squibb's 2011 fourth-quarter earnings conference call. This call is being recorded. At this time, I would like to turn the call [...]

Published
2012

37. Q3 2011 Transgenomic Inc Earnings Conference Call - Final

Subjects
Transgenomic Inc. -- Distribution agreements -- Planning, Medicare -- Distribution agreements -- Planning, Biotechnology industry -- Distribution agreements -- Planning, Peace movements, Capital stock -- Distribution agreements -- Planning, Preferred stocks -- Distribution agreements -- Planning, Pharmaceutical industry -- Distribution agreements -- Planning, Company business planning, Business, Plavix (Medication)
Abstract

Presentation OPERATOR: Good day and welcome to the Transgenomic third quarter 2011 financial results conference call. (Operator Instructions) Also note today's conference may be recorded. I'll now turn the program [...]

Published
2011

38. Q3 2011 Sanofi SA Earnings Conference Call - Final

Subjects
Pfizer Inc., Arab Spring, 2010-2012, Medicare, Corporations, Pharmaceutical industry, Business, Cerezyme (Medication), Jevtana (Medication), Fabrazyme (Medication), Lantus (Medication), Lovenox (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Welcome to the 2011 Q3 results conference call. Today, I'm pleased to present Mr. Sebastien Martel. Sir, please go ahead. SEBASTIEN MARTEL, IR, SANOFI SA: Thank you. Hello, [...]

Published
2011

39. Event Brief of Q3 2011 Bristol-Myers Squibb Earnings Conference Call - Final

Subjects
Barclays Capital Inc. -- Planning, Bristol-Myers Squibb Co. -- Planning, Investment banks -- Planning, Property and casualty insurance industry -- Planning, Pharmaceutical industry -- Planning, Company business planning, Business, Yervoy (Medication), Orencia (Medication), Plavix (Medication)
Abstract

PARTICIPANTS . John Elicker, Bristol Myers Squibb Co, VP IR . Lamberto Andreotti, Bristol Myers Squibb Co, President and COO . Charlie Bancroft, Bristol Myers Squibb Co, EVP, CFO . [...]

Published
2011

40. Q3 2011 BristolMyers Squibb Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co. -- Officials and employees -- Planning, Property and casualty insurance industry -- Officials and employees -- Planning, Pharmaceutical industry -- Officials and employees -- Planning, Company business planning, Business, Yervoy (Medication), Orencia (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to today's third quarter 2011 earnings release conference call. This call is being recorded. At this time I would like to turn the call [...]

Published
2011

41. Sanofi SA IR Thematic Seminar 'Strategy & Outlook' Conference Call - Final

Subjects
Societe Generale S.A. -- Intellectual property -- Planning, Sanofi S.A. -- Intellectual property -- Planning, Selling, Financial markets, Anticoagulants (Medicine), Banking industry -- Intellectual property -- Planning, Global temperature changes, Product life cycle, Prediabetic state -- Development and progression, Medical care, Cost of, Medicine, Experimental, Corporations, Developing country, Diabetes therapy -- Planning, Trademarks, Biological response modifiers, Enzymes -- Planning, Biological products industry -- Intellectual property -- Planning, Medical research, Corporations, Developing countries, Hypercholesterolemia -- Development and progression, Pets, Low density lipoproteins, Pharmaceutical industry -- Intellectual property -- Planning, Sustainable development, Biopharmaceutics -- Planning, Multiple sclerosis -- Development and progression, Metastasis -- Development and progression, Influenza -- Development and progression, Antigens, Veterinary supplies industry -- Intellectual property -- Planning, Public health, Vaccines -- Planning, Whooping-cough -- Development and progression, Monoclonal antibodies, Fashion -- Planning, Guided missiles -- Guidance systems, Company business planning, Banking industry, Business, Cerezyme (Medication), Fabrazyme (Medication), Avapro (Medication), Lantus (Medication), Plavix (Medication)
Abstract

Presentation SEBASTIEN MARTEL, VP - IR, SANOFI AVENTIS: Good afternoon and welcome to our Investor Relations Seminar on Strategy and Outlook. I think this is a format you've now been [...]

Published
2011

42. Event Brief of Q2 2011 Bristol Myers Squibb Co Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co., Medicare, Pharmaceutical industry, Business, Orencia (Medication), Plavix (Medication)
Abstract

PARTICIPANTS . John Elicker, Bristol Myers Squibb Co, VP, Investor Relations . Lamberto Andreotti, Bristol Myers Squibb Co, President and COO . Charlie Bancroft, Bristol Myers Squibb Co, CFO . [...]

Published
2011

43. Q2 2011 Bristol Myers Squibb Co Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co., Medicare, Pharmaceutical industry, Business, Orencia (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to today's the second quarter 2011 conference call. This call is being recorded. At this time I would like to turn the call over [...]

Published
2011

44. Event Brief of Q2 2011 Medicines Co Earnings Conference Call - Final

Subjects
Leerink Swann and Co., Executions and executioners, Financial markets, Investment banks, Business, Cleviprex (Medication), Angiomax (Medication), Plavix (Medication)
Abstract

PARTICIPANTS . Michael Mitchell, The Medicines Company, Head of Communications . Clive Meanwell, The Medicines Company, Chairman and CEO . Glenn Sblendorio, The Medicines Company, EVP and CFO . Dimitri [...]

Published
2011

45. Q2 2011 Medicines Co Earnings Conference Call - Final

Subjects
Financial markets, Business, Cleviprex (Medication), Angiomax (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to the Q2 2011 Medicines Company earnings conference call hosted by Michael Mitchell, Head of Communications. My name is Mamoud. I'm [...]

Published
2011

46. Bristol Myers Squibb Co at Goldman Sachs Global Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Medicine -- Practice, Diabetes therapy -- Conferences, meetings and seminars -- Usage, Generic drugs -- Conferences, meetings and seminars -- Usage, Investment banks -- Conferences, meetings and seminars -- Usage, Warfarin -- Conferences, meetings and seminars -- Usage, Melanoma -- Care and treatment -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Plavix (Medication)
Abstract

Presentation UNIDENTIFIED PARTICIPANT: Okay, everybody. I am excited, delighted to be hosting this session with Tony Hooper from Bristol-Myers. Tony is Senior Vice President of Commercial Operations, he is President [...]

Published
2011

47. Q1 2011 BristolMyers Squibb Co Earnings Conference Call - Final

Subjects
Bristol-Myers Squibb Co. -- Planning, Biological products industry -- Planning, Wholesale industry, Pharmaceutical industry -- Planning, Company business planning, Wholesale dealer/distributor, Business, American Society of Clinical Oncology -- Planning, Onglyza (Medication), Avapro (Medication), Sprycel (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to today's first-quarter earnings 2011 earnings release conference call. This call is being recorded. At this time, I would like to turn the call [...]

Published
2011

48. Q1 2011 Nanosphere Inc Earnings Conference Call - Final

Subjects
Nanosphere Inc., Biotechnology industry, Business, Plavix (Medication)
Abstract

Presentation OPERATOR: Good day, ladies and gentlemen, and welcome to First Quarter 2011 Nanosphere Earnings Conference Call. My name is Karma and I'll be your coordinator for today. At this [...]

Published
2011

49. Full Year 2010 Sanofi-Aventis Earnings Conference Call - Final

Subjects
Merck & Company Inc. -- Reorganization and restructuring, Societe Generale S.A. -- Reorganization and restructuring, Sanofi S.A. -- Reorganization and restructuring, Banking industry -- Reorganization and restructuring, Pharmaceutical industry -- Reorganization and restructuring, Company organization, Company restructuring/company reorganization, Banking industry, Business, Multaq (Medication), Eloxatin (Medication), Lantus (Medication), Lovenox (Medication), Plavix (Medication), Taxotere (Medication)
Abstract

SEBASTIEN MARTEL, VP IR, SANOFI-AVENTIS: Okay, well good afternoon and good morning to those of you following us from the US. Welcome to our 2010 annual results conference. As you [...]

Published
2011

50. Event Brief of Full Year 2010 Sanofi-Aventis Earnings Conference Call - Final

Subjects
Merck & Company Inc. -- Intellectual property -- Reorganization and restructuring, Credit Suisse Group AG -- Intellectual property -- Reorganization and restructuring, BNP Paribas S.A. -- Intellectual property -- Reorganization and restructuring, Societe Generale S.A. -- Intellectual property -- Reorganization and restructuring, Biological products industry -- Intellectual property -- Reorganization and restructuring, Corporations, Chronic diseases, Banking industry -- Intellectual property -- Reorganization and restructuring, Financial services industry -- Intellectual property -- Reorganization and restructuring, Pharmaceutical industry -- Intellectual property -- Reorganization and restructuring, Company organization, Financial services industry, Company restructuring/company reorganization, Banking industry, Business, Multaq (Medication), Eloxatin (Medication), Lantus (Medication), Lovenox (Medication), Plavix (Medication), Taxotere (Medication)
Abstract

PARTICIPANTS . Sebastien Martel, Sanofi-Aventis, VP IR . Chris Viehbacher, Sanofi-Aventis, CEO . Jerome Contamine, Sanofi-Aventis, CFO . Hanspeter Spek, Sanofi-Aventis, President, Global Operations . Olivier Charmeil, Sanofi-Aventis, SVP, Vaccines [...]

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results